Targeting the PI3K/AKT/mTOR pathway in ovarian cancer

被引：12

作者：

Musa, Fernanda ^{[1
]}

Schneider, Robert ^{[2
]}

机构：

[1] NYU, Dept Obstet & Gynecol, Langone Med Ctr, New York, NY 10016 USA

[2] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA

来源：

TRANSLATIONAL CANCER RESEARCH | 2015年 / 4卷 / 01期

关键词：

Ovarian cancer; mTOR inhibitors; rapalogs; dual mTOR inhibitors; PI3K inhibitors; AKT inhibitors; PI3K/mTOR inhibitors; clinical trials; MAMMALIAN TARGET; MTOR INHIBITOR; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; PHASE-I; CELL; RAPAMYCIN; TEMSIROLIMUS; ACTIVATION; ONCOGENE;

D O I：

10.3978/j.issn.2218-676X.2015.01.10

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is the most common cause of mortality in U.S. women with gynecologic cancers. Without a successful screening strategy, most women present with advanced disease associated with a poor overall survival (OS) at 5 years despite high response rates to first line chemotherapy. Preclinical data points to the importance of PI3K/AKT/mTOR pathway activation in ovarian cancer tumorigenesis. Strategies to inhibit specific kinases in this pathway have been successful in laboratory studies and preliminary clinical trials. This review highlights the rationale behind the use of PI3K/AKT/mTOR inhibitors in clinical trials and thoroughly reviews the available therapeutic compounds and registered clinical trials to date. It outlines the importance of targeted clinical trials and the populations most likely to benefit from this strategy. It is with great anticipation that we await the results of the upcoming registered clinical trials and the opportunity to offer this novel therapeutic strategy to our patients with ovarian cancer.

引用

页码：97 / 106

页数：10

共 51 条

[1] AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth [J].

Altomare, DA ;

Wang, HQ ;

Skele, KL ;

De Rienzo, A ;

Klein-Szanto, AJ ;

Godwin, AK ;

Testa, JR .

ONCOGENE, 2004, 23 (34) :5853-5857

[2] DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs [J].

Badura, Michelle ;

Braunstein, Steve ;

Zavadil, Jiri ;

Schneider, Robert J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (46) :18767-18772

[3] Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study [J].

Behbakht, Kian ;

Sill, Michael W. ;

Darcy, Kathleen M. ;

Rubin, Stephen C. ;

Mannel, Robert S. ;

Waggoner, Steven ;

Schilder, Russell J. ;

Cai, Kathy Q. ;

Godwin, Andrew K. ;

Alpaugh, R. Katherine .

GYNECOLOGIC ONCOLOGY, 2011, 123 (01) :19-26

[4] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[5] MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS [J].

BELLACOSA, A ;

DEFEO, D ;

GODWIN, AK ;

BELL, DW ;

CHENG, JQ ;

ALTOMARE, DA ;

WAN, MH ;

DUBEAU, L ;

SCAMBIA, G ;

MASCIULLO, V ;

FERRANDINA, G ;

PANICI, PB ;

MANCUSO, S ;

NERI, G ;

TESTA, JR .

INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) :280-285

[6] The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].

Cerami, Ethan ;

Gao, Jianjiong ;

Dogrusoz, Ugur ;

Gross, Benjamin E. ;

Sumer, Selcuk Onur ;

Aksoy, Buelent Arman ;

Jacobsen, Anders ;

Byrne, Caitlin J. ;

Heuer, Michael L. ;

Larsson, Erik ;

Antipin, Yevgeniy ;

Reva, Boris ;

Goldberg, Arthur P. ;

Sander, Chris ;

Schultz, Nikolaus .

CANCER DISCOVERY, 2012, 2 (05) :401-404

[7] The cell of origin of ovarian epithelial tumours [J].

Dubeau, Louis .

LANCET ONCOLOGY, 2008, 9 (12) :1191-1197

[8]

Edwards R, STUDY RAD001 BEVACIZ

[9] The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain [J].

Edwards, Sarah R. ;

Wandless, Thomas J. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (18) :13395-13401

[10] Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers [J].

Engel, Joerg B. ;

Schoenhals, Tanja ;

Haeusler, Sebastian ;

Krockenberger, Mathias ;

Schmidt, Melanie ;

Horn, Evi ;

Koester, Frank ;

Dietl, Johannes ;

Wischhusen, Joerg ;

Honig, Arnd .

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2011, 283 (03) :603-610

← 1 2 3 4 5 6 →